文献速递血栓与止血

2025年血友病、血管性血友病及罕见遗传性出血性疾病临床试验更新

2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders.
PubMed 文献 · Am J Hematol · 2025-02-04

本文综述了遗传性出血性疾病正在进行的临床试验,涵盖工程化凝血因子浓缩物、FVIIIa模拟物、基因治疗及增强凝血酶生成的生物制剂等预防治疗选项,并涉及血管性血友病、血小板功能缺陷和罕见凝血因子缺乏症等非血友病出血性疾病及女性、儿童和婴儿等更广泛人群。试验主题包括已获批药物的适应症扩展、其他出血性疾病的疗效与安全性评估,以及已批准治疗的长期疗效与安全性评估。

要点

  • 遗传性出血性疾病临床试验涵盖工程化凝血因子、FVIIIa模拟物、基因治疗和增强凝血酶生成的生物制剂。
  • 非血友病出血性疾病及女性、儿童和婴儿正越来越多地被纳入研究人群。
  • 试验主题包括适应症扩展、其他出血性疾病评估及已批准治疗的长期疗效与安全性评估。

核心结论

  • 随着新的预防治疗模式出现,提供者必须细致理解每种疗法的作用机制、优势、副作用特征、治疗局限及对止血和实验室监测的影响。
  • 治疗不再是一刀切,而是根据个体需求和偏好进行定制。

研究设计与样本

  • 本文为综述,回顾了正在进行的试验性研究,并重点介绍了临床前开发中有前景的方法。

主要发现

  • 正在进行的临床试验广泛涉及三个主题:已获批治疗在先前未研究的患者亚组或临床场景中的适应症扩展;在血管性血友病、血小板功能缺陷和罕见凝血因子缺乏症等其他出血性疾病中评估疗效和安全性;对已批准治疗进行纵向评估,尤其关注长期疗效结局如肌肉骨骼健康,以及治疗特异性安全性结局包括血栓风险和肝脏健康。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trial programs for inherited bleeding disorders feature an array of innovative prophylaxis options: engineered clotting factor concentrates, FVIIIa mimetics, gene therapies, and biologics to bolster thrombin generation (rebalancing agents). Increasingly, non-hemophilia bleeding disorders and a broader demographic (females, children, and infants) are being incorporated into study populations. Ongoing clinical trials broadly address three themes: (1) indication expansion for licensed therapeutics in previously uninvestigated patient subgroups or clinical scenarios, (2) evaluation of efficacy and safety among other bleeding disorders such as von Willebrand disease, platelet function defects, and rare clotting factor deficiencies, and (3) longitudinal assessment of approved treatments particularly with regard to longer-term efficacy outcomes such as musculoskeletal health and treatment-specific safety outcomes including thrombotic risk and liver health. With these new prophylaxis modalities, providers must have a nuanced understanding of each therapy's mechanism of action, advantages, side effect profile, therapeutic limitations, and impact on hemostasis and laboratory monitoring. Treatment is no longer "one size fits all." Rather, management is tailored to individual needs and preferences. Here, we review active investigational trials and highlight promising approaches in preclinical development, expanding the innovative, complex landscape of inherited bleeding disorders therapeutics.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jiang D, Wang M, Wheeler AP, et al. 2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders. Am J Hematol. 2025. PMID: 39901862. doi:10.1002/ajh.27602

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。